SO-27 Efficacy and response rates of the RENCA Macrobead therapy (RMB): A novel approach to the treatment of metastatic colorectal cancer. phase II clinical trials [U.S. FDA BB-IND 10091]

Abstract

BRAF signaling in combination with immune checkpoint inhibition could enhance activity.Methods: BRAFV600E CRC patients recruited from the Massachusetts General Hospital Cancer Center or the Dana-Farber Cancer Institute were treated with the PD-1 inhibitor spartalizumab (PDR001) 400mg IV q28d, dabrafenib 150mg PO BID, and trametinib 2mg PO daily. Single-cell RNAseq was performed on paired baseline and day 15 tumor biopsies, patient-derived organoids were established from baseline biopsies, and serial ctDNA was analyzed.